IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

Artios Pharma, a UK-based cancer therapy developer, secured $153m in a series C round on Tuesday from investors including commercialisation firm IP Group. Investment firms Omega Funds and TCG Crossover co-led the round, which included the corporate venture capital units of pharmaceutical firms Merck Group, Novartis and Pfizer – M Ventures, Novartis Venture Fund and…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.